Levosimendan Kalceks

Levosimendan, the active ingredient in Levosimendan Kalceks, is a calcium sensitizer presented as an intravenous solution for intravenous use. It is employed in the management of acute decompensated heart failure to improve cardiac contractility in adult patients.

GNH USA supplies Levosimendan Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company provides the product to cardiac care units, transplant centres and specialty pharmacies across EU and other regulated markets, adhering to strict quality standards and ensures timely delivery.

Levosimendan is indicated for conditions involving impaired cardiac contractility and acute heart failure.

Acute decompensated heart failure: improves myocardial contractility and reduces filling pressures, helping to restore adequate cardiac output. Post‑cardiac surgery low cardiac output syndrome: supports hemodynamics while allowing reduction of catecholamine support. Severe heart failure awaiting transplantation: provides temporary circulatory support to stabilize patients.

Levosimendan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Hypotension: reduction in blood pressure, especially during infusion. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate, usually dose‑related.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion. - Severe hypotension: profound blood pressure drop requiring intervention. - Allergic reactions: rash, pruritus, or anaphylaxis in susceptible individuals.

Levosimendan should be used with careful clinical monitoring and consideration of patient‑specific factors.

Renal impairment: dose adjustment may be required and renal function should be monitored. Hepatic impairment: monitor liver enzymes and consider reduced dosing. Hypotension: blood pressure should be measured before and during infusion. Concomitant vasodilators: use with caution due to additive hypotensive effects. Pregnancy: safety not established; avoid unless benefit outweighs risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Sodium nitroprusside: additive vasodilation may cause severe hypotension. - Phosphodiesterase‑5 inhibitors: risk of profound blood pressure reduction. - Strong CYP3A4 inhibitors: increase levosimendan plasma concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt chronotropic response, requiring heart‑rate monitoring. - Diuretics: can exacerbate electrolyte shifts, necessitating regular labs. - ACE inhibitors: monitor blood pressure for additive hypotensive effect.